Staphylococcus epidermidis is a conspicuous member of the human microbiome, widely present on healthy skin. Here we show that S. epidermidis has also evolved to become a formidable nosocomial pathogen. Using genomics, we reveal that three multidrug-resistant, hospital-adapted lineages of S. epidermidis (two ST2 and one ST23) have emerged in recent decades and spread globally. These lineages are resistant to rifampicin through acquisition of specific rpoB mutations that have become fixed in the populations. Analysis of isolates from 96 institutions in 24 countries identified dual D471E and I527M RpoB substitutions to be the most common cause of rifampicin resistance in S. epidermidis, accounting for 86.6% of mutations. Furthermore, we reveal that the D471E and I527M combination occurs almost exclusively in isolates from the ST2 and ST23 lineages. By breaching lineage-specific DNA methylation restriction modification barriers and then performing site-specific mutagenesis, we show that these rpoB mutations not only confer rifampicin resistance, but also reduce susceptibility to the last-line glycopeptide antibiotics, vancomycin and teicoplanin. Our study has uncovered the previously unrecognized international spread of a near pandrug-resistant opportunistic pathogen, identifiable by a rifampicin-resistant phenotype. It is possible that hospital practices, such as antibiotic monotherapy utilizing rifampicin-impregnated medical devices, have driven the evolution of this organism, once trivialized as a contaminant, towards potentially incurable infections. Ongoing cases of similarly pan-resistant S. epidermidis infections in unrelated patients within our hospital suggested dissemination of a multidrug-resistant lineage. We began investigations using comparative and functional genomics to characterize the molecular epidemiology and resistance mechanisms of S. epidermidis linked to clinically significant infections, initially within our institution and then globally.
S
taphylococcus epidermidis is universally present on human skin 1 . The shift in medicine towards invasive procedures has favoured its emergence as a significant nosocomial pathogen, particularly in the setting of prosthetic devices 2 . The ability of the bacterium to form biofilms over foreign bodies, in which bacteria are protected from antibiotics and the immune system, is key in the evolution of disease 3 . S. epidermidis and other coagulasenegative staphylococci (CoNS) are leading causes of surgical site and central-line-associated bloodstream infections 4 , with major economic implications 5 . In spite of this impact, relatively little is understood about the mechanisms of pathogenesis and optimal treatment of S. epidermidis. Many of the clinical decisions made when treating this species are based on assumptions from studies in Staphylococcus aureus.
A single S. epidermidis lineage, multilocus sequence type (MLST) 2, dominates in the hospital environment. MLST eBURST analysis of a global strain collection found 74% of nosocomial isolates belong to clonal complex 2, for which ST2 is the founder 6 .
The S. epidermidis population structure, as assessed by MLST, comprises six genetic clusters (GCs) 7, 8 . Isolates from GC5 (encompassing ST2 and ST23) are almost exclusively nosocomial 8 and significantly enriched for antibiotic resistance and biofilm production, suggesting hospital adaptation 7 . Methicillin resistance in S. epidermidis has been reported to be as high as 70-92% in some institutions 9 , and is frequently associated with co-resistance to other antibiotic classes 10, 11 . We recently reported the first complete genome and methylome of BPH0662, an ST2 S. epidermidis exhibiting near pan-drug resistance, including intermediate heteroresistance to vancomycin, responsible for a serious post-neurosurgical infection 12 . Vancomycin intermediate heteroresistance is characterized by the presence of bacterial subpopulations capable of growth within the intermediate range, despite testing as vancomycin-susceptible by standard laboratory methods. Few studies have described the phenomenon in S. epidermidis 13, 14 or CoNS collectively [15] [16] [17] . The diagnostic definitions and clinical implications of S. epidermidis
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, these isolates were also resistant to β -lactams, macrolides, quinolones, aminoglycosides and sulfonamides, indicating the emergence of multidrug-resistant S. epidermidis (MDRSE) within our institution. Using rifampicin and fusidic acid resistance as markers for MDRSE, 52 clinically significant MDRSE isolates were identified, of which 33 were available for further testing. Thirty-five clinically significant non-MDRSE comparator strains, two non-MDRSE reference strains (ATCC 12228 18 and RP62a 19 ), BPH0662 and BPH0663 (subsequent isolate from the index case) were also included in analyses (full antibiograms are shown in Supplementary  Fig. 1 ). In S. aureus, specific rifampicin resistance mutations in rpoB result in vancomycin heteroresistance 20, 21 . We postulated that MDRSE vancomycin heteroresistance might also be explained by rifampicin resistance mutations. Macromethod Etests (METs) are a sensitive method for the detection of reduced glycopeptide susceptibility in staphylococci 22 . METs performed on these 72 isolates revealed a significant association with heteroresistance to vancomycin ( Fig. 1c) and teicoplanin ( Fig. 1d) for MDRSE compared to non-MDRSE (P < 0.0001 for both).
International clonal expansion of endemic, multidrug-resistant, ST2 and ST23 S. epidermidis lineages resulting in clinical disease.
To investigate the relationship between clinically significant isolates of MDRSE and non-MDRSE at our institution, whole-genome comparisons were made of the 72 isolates plus two additional published, finished S. epidermidis genomes. A maximum-likelihood phylogeny was inferred from an alignment of 54,493 core genome single nucleotide polymorphisms (SNPs) (Fig. 2 ). Bayesian analysis of population structure (BAPS), derived from core-SNP analysis, categorized the 74 genomes into five groups (named A-E). The largest (group E) represented ST2, accounting for 59% of isolates and consisted of two dominant sublineages, one MDRSE (n = 27), to which the BPH0662 reference belonged, the other predominantly non-MDRSE (n = 16), of which two were MDRSE (henceforth referred to as the ST2-mixed lineage). A third cluster of five MDRSE isolates belonging to the ST23 lineage (BAPS group C) was also identified (Fig. 2) . The presence of isolates from three distinct lineages across at least six years indicated that each was endemic within our institution, resulting in repeated, clinically significant, nosocomial infections.
We next sought to determine the broader distribution of these three MDRSE lineages across Australia and globally. A further 32 rifampicin-resistant clinical S. epidermidis isolates from 13 institutions in Australia, and 121 global isolates from Austria (n = 1), Belgium (n = 18), Denmark (n = 38), France (n = 18), Germany (n = 21), Republic of Ireland (n = 1), United Kingdom (n = 12) and the United States (n = 12) originating from 61 institutions were collected, totalling 227 isolates (Supplementary Table 1a) .
A maximum-likelihood phylogeny for the 227 isolates was inferred from an alignment of 56,756 core genome SNPs and revealed the same basic population structure as before, with the majority of isolates clustered into three MDRSE lineages ( Fig. 3 and Supplementary Fig. 2a) . Overall, core-SNP-based comparisons suggested high genomic identity within the BPH0662 lineage, with a median pairwise SNP difference of 62 SNPs (interquartile range (IQR) . In contrast, the median difference within the ST2-mixed clade was 281.5 SNPs (IQR 190.25-378), indicating more genetic diversity among ST2-mixed isolates. Compared to one another, the two ST2 lineages were distinct with a median of 1,669 SNPs (IQR 1,649-1,703) between them (Fig. 3b,c) . The ST23 MDRSE also demonstrated high intra-lineage identity with a median difference of 103 SNPs (IQR 88-116), while the ST5 lineage was composed of heterogeneous isolates with a median intra-group difference of 374 SNPs (IQR 141-587) (Fig. 3c) .
The BPH0662 ST2 MDRSE lineage, dominant in Australia, was also identified from 25 institutions in four countries (Australia, Belgium, Denmark and the United Kingdom) and persisted within two Australian sites for at least 8 years, while the ST2-mixed lineage was identified in 33 institutions within seven countries (Australia, Belgium, Denmark, France, Germany, Ireland and the United Kingdom). The ST23 lineage was present in 17 institutions across seven countries (Australia, Austria, Belgium, Denmark, France, Germany and the United States); this lineage persisted up to 17 years in Denmark and 15 years at a single site in the United States. Co-circulation of all three clones was observed in two of the European sites (BEL-A and DEN-G). While isolates from the same country tended to cluster within each of the three MDRSE lineages, genotype intermingling was also observed across countries, consistent with the international dissemination of three individual successful clones ( Fig. 3 and Supplementary Fig. 2 ).
Pan-genome analysis identified 5,692 orthologue gene clusters. Minimal variability in gene content was observed within the BPH0662 ST2 clade (Supplementary Fig. 2c ). The accessory gene content specific to this lineage was the same as previously characterized for BPH0662, and clustering based on genome content aligned strongly with core genome phylogeny ( Supplementary  Fig. 2d ), the MDRSE ST2-mixed lineage contained similar accessory gene content ( Supplementary Fig. 2c ). All ST2 and subclustered ST188 (n = 133) and ST23 (n = 50) isolates possessed the icaRADBC operon, which was not present in any of the ST5 or subclustered ST87 (n = 15) isolates. The ica operon was highly conserved among 193 isolates ( Supplementary Fig. 2c ). Orthologue clustering clearly demonstrated that RP62a (ST10), a reference isolate frequently used in laboratory experiments, is an outlier compared to other clinical isolates ( Supplementary Fig. 2d ).
Evolutionary phylogeny suggests independent coevolution of two ST2 and one ST23 multidrug-resistant S. epidermidis lineages. To model the evolutionary trajectory of S. epidermidis and date the emergence of the drug-resistant ST23 and ST2 lineages, we used core genome SNP diversity and year of isolation to infer a timescaled phylogeny in a Bayesian framework (Supplementary Fig. 3 
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Genetic determinants of antibiotic resistance. Ninety-nine percent of the 133 ST2 isolates possessed mecA (Supplementary Table 1d ), which correlated with the antibiogram data ( Supplementary Fig. 1 ). RP62a  BPH0703  BPH0715  BPH0666  BPH0695  BPH0713  BPH0723  BPH0690  BPH0739  BPH0684  BPH0711  BPH0673  BPH0667  BPH0726  BPH0689  BPH0734  BPH0738  12228  BPH0700  BPH0729  PM221  SEI  BPH0677  BPH0737  BPH0707  BPH0699  BPH0721  BPH0693  BPH0736  BPH0708  BPH0710  BPH0724  BPH0671  BPH0676  BPH0719  BPH0730  BPH0681  BPH0705  BPH0722  BPH0716  BPH0717  BPH0669  BPH0732  BPH0706  BPH0694  BPH0702  BPH0670  BPH0672  BPH0686  BPH0674  BPH0679  BPH0678  BPH0668  BPH0687  BPH0733  BPH0685  BPH0663  BPH0662  BPH0675  BPH0731  BPH0696  BPH0709  BPH0728  BPH0712  BPH0718  BPH0720  BPH0714  BPH0735  BPH0727 Table 2 ). All five of the cfr-positive isolates were from Germany, three of which had acquired S. epidermidis plasmid p12-02300 (accession no. KM521837) previously associated with an outbreak of linezolid resistance in German hospitals 25 , one had a previously undescribed plasmid. Twelve isolates were resistant to daptomycin, two of which (AUS14 and FRA09) had an MprF S295L substitution, known to cause daptomycin resistance 27 . Due to the pleiotropic nature of daptomycin resistance, other potential causative mutations were not identified.
Two co-occurring mutations in RpoB, D471E and I527M, explained rifampicin resistance for 163 of the 187 isolates in this study. Two isolates had alternative D471 substitutions. The remaining had at least one RpoB substitution occurring at site H481 (n = 7), S486 (n = 13), V135 (n = 2) and N353 (n = 1) ( Supplementary  Figs. 2 and 4) . Based on alignment with the known sequence defined for other bacterial species, the rifampicin resistance determining region (RRDR) in S. epidermidis spanned amino-acid positions 462 to 488 (inclusive). Three critical positions known to form covalent bonds with rifampicin in other species (at which most rifampicinresistant mutations occur) 28, 29 were determined to correspond to D471, H481 and S486. Although outside the RRDR, sites V135 and I527 aligned with positions also known to be associated with rifampicin resistance in other bacterial species 28, 29 . Glycopeptide susceptibility testing found the majority of isolates with the dual RpoB RP62a  US07  US09  US02  US04  US03  BPH0666  BPH0695  BPH0713  FRA01  FRA14  DEN34  FRA17  GER15  GER19  BEL02  BEL03  BEL17  BEL05  FRA07  DEN20  DEN18  DEN21  BPH0715  FRA16  BPH0703  DEN02  DEN09  DEN11  DEN35  AUT01  GER08  DEN37  DEN22  DEN30  DEN31  AUS27  AUS28  DEN14  DEN16  DEN36  DEN12  DEN32  DEN13  DEN24  DEN26  DEN33  DEN19  DEN27  DEN25  DEN29  FRA02  US11  BPH0690  BPH0739  US01  BEL06  FRA04  GER21  US05  US08  FRA06  UK04  DEN23  US06  BPH0723  US12  GER13  GER07  GER10  PM221  SEI  BPH0677  BPH0737  12228  FRA09  BPH0700  BPH0729  BPH0707  BPH0699  BPH0721  US10  BPH0684  FRA08  BPH0711  BPH0673  BPH0667  BPH0726  BPH0689  BPH0734  BPH0738  DEN15  DEN38  AUS18  AUS05  AUS09  AUS17  AUS21  AUS22  BPH0669  BPH0732  AUS07  GER04  GER05  GER06  DEN03  AUS26  GER03  GER11  FRA18  FRA10  FRA05  FRA11  GER01  GER17  FRA15  FRA12  GER02  GER09  GER12  GER20  GER16  GER18  FRA13  BEL04  BEL18  BEL10  BEL13  AUS15  BPH0693  IRL01  BEL09  BEL01  BEL11  FRA03  BPH0736  BPH0708  BPH0710  BPH0681  BPH0705  BPH0722  BPH0716  BPH0717  BPH0724  BEL14  AUS16  UK01  BPH0671  BPH0676  BPH0719  BPH0730  BPH0706  GER14  BEL07  BEL12  BEL15  DEN07  DEN06  DEN08  DEN01  DEN05  DEN04  DEN10  UK07  UK08  DEN17  UK11  BEL08  BEL16  UK02  UK10  UK12  UK03  UK05  UK06  AUS25  AUS10  BPH0694  BPH0702  BPH0670  AUS23  BPH0686  BPH0672  AUS04  BPH0674  AUS02  BPH0679  BPH0678  BPH0668  AUS11  AUS19  AUS32  BPH0687  AUS14  AUS03  AUS06  BPH0733  BPH0685  BPH0663  BPH0662  UK09  AUS01  AUS12  BPH0675  AUS29  AUS08  AUS30  AUS20  AUS24  BPH0731  BPH0696  BPH0709  DEN28  BPH0728  AUS13  AUS31  BPH0712  BPH0718  BPH0720  BPH0714  BPH0735  BPH0727  BPH0691  BPH0692 VAN TEC DEN07  DEN06  DEN08  DEN01  DEN05  DEN04  DEN10  DEN17  UK07  UK08  UK11  BEL08  BEL16  UK02  UK10  UK12  UK03  UK05  UK06  AUS25  AUS10  BPH0694  BPH0702  UK09  BPH0670  AUS23  BPH0686  BPH0672  AUS04  BPH0674  AUS02  BPH0679  BPH0678  BPH0668  AUS11  AUS19  AUS32  BPH0687  AUS14  AUS03  AUS06  BPH0663  BPH0662  BPH0685  BPH0733  AUS01  AUS12  BPH0675  AUS29  AUS08  AUS30  AUS20  AUS24  BPH0731  BPH0696  BPH0709  DEN28  BPH0728  AUS13  AUS31  BPH0712  BPH0718  BPH0720  BPH0714  BPH0735  BPH0727  BPH0691 US07  US09  US03  US02  US04  BPH0666  BPH0695  BPH0713  FRA14  DEN34  FRA01  FRA17  GER15  GER19  BEL02  BEL03  BEL17  BEL05  FRA07  DEN18  DEN21  BPH0715  FRA16  BPH0703  DEN02  DEN09  DEN11  DEN20  DEN35  AUT01  GER08  DEN37  DEN31  DEN22  DEN30  AUS27  AUS28  DEN36  DEN12  DEN32  DEN14  DEN16  DEN13  DEN24  DEN19  DEN33  DEN26  DEN25  DEN27 (A)   +1   +1   D471E, I527M  D471E, I527M, +1 aa mutation  D471Y, I527M  D471N  S486F  S486Y  H481D  H481Y  H481L  H481N  H481R Inter-group Intra-group DEN15  DEN38  AUS18  AUS05  AUS09  AUS17  AUS21  AUS22  AUS07  BPH0669  BPH0732  GER04  GER05  GER06  DEN03  AUS26  GER03  GER11  FRA18  FRA10  FRA05  FRA11  GER01  GER17  FRA15  FRA12  GER02  GER09  GER12  GER20  GER16  GER18  FRA13  BEL18  BEL04  BEL10  BEL13  AUS15  BPH0693  IRL01  BEL09  BEL01  BEL11  FRA03  BPH0736  BPH0708  BPH0710  BPH0681  BPH0705  BPH0716  BPH0717  BPH0722  BPH0724  AUS16  UK01  BEL14  BPH0671  BPH0676  BPH0719  BPH0730   8  1 2  6  1 2  8  1 2  6  1 6  6  1 2  8  1 2  8  1 2  6  1 2  8  1 2  8  1 2  8  1 6  12  12  6  1 2  12  12  8  1 6  12  48  12  24  12  24  8  8  12  48  8  1 6  8  2 4  12  32  8  3 2  8  3 2  6  2 
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D471E and I527M mutations (96.9%) or single RpoB H481D/L/R/Y substitutions (100%) were vancomycin heteroresistant ( Fig. 3 and Supplementary Fig. 2 ).
Dual D471E and I527M substitutions are the most common RpoB mutations in S. epidermidis worldwide. To confirm that the dominant RpoB mutations observed in our study were representative of other S. epidermidis globally, we performed an analysis of all publicly available S. epidermidis sequence data. Using the selection/ exclusion criteria outlined in the Methods, a curated list of 160 clinical isolates (see Supplementary Table 1 for full metadata) downloaded from NCBI Sequence Read Archive (SRA) were assembled, and the rpoB genes analysed in conjunction with the four NCBI reference strains and the 222 isolates from this study (BPH0663 was excluded as an in vivo serial isolate of BPH0662); data from a Swedish study by Hellmark et al. 30 in which the rpoB gene of 33 S. epidermidis strains isolated from prosthetic joint infections were sequenced and correlated with phenotype were also included. Of the 419 isolates analysed, 251 were identified as having at least one of 40 putative amino-acid substitutions in RpoB, occurring across 32 sites. The dual D471E and I527M substitutions were the most common, present in 187 of the isolates, accounting for 73.9% of the observed mutations, and 86.6% of the mutations occurring within the RRDR of RpoB ( Supplementary Fig. 4) . Interestingly, neither D471E nor I527M were observed as solitary substitutions. Analysis of metadata indicated that isolates possessing the dual mutations originated from 68 different institutions in 11 countries, and in silico MLST demonstrated ST2 (62.9%) and ST23 (33.1%), accounted for 96.0% of isolates with the dual D471E and I527M substitutions.
Dual D471E and I527M mutations in RpoB confer co-resistance to rifampicin and vancomycin in S. epidermidis. To confirm a causal link between these mutations and vancomycin heteroresistance we swapped the D471E and I527M rpoB allele from BPH0662 into four rifampicin-susceptible S. epidermidis backgrounds-two clinical, non-MDRSE ST2 strains, BPH0676 and BPH0736; and reference strains RP62a (ST10) and ATCC 12228 (ST8)-using plasmid artificial modification and allelic exchange. Acquisition of rifampicin resistance enabled positive screening of mutants. Whole-genome sequencing confirmed the presence of only the intended two substitutions in rpoB, with the exception of 12228-rpoB662, which acquired an additional spontaneous SNP leading to a M305L substitution in a hypothetical regulatory protein (locus_ tag SE2129). To the best of our knowledge, this is the first successful report of allelic exchange in ST2 S. epidermidis.
Compared to the four wild-type (WT) parental strains-BPH0676, BPH0736, RP62a and ATCC 12228-all rpoB662 mutants acquired high-level rifampicin resistance equivalent to that of BPH0662 (64 μ g ml
−1
). The mutants were not identified as glycopeptide resistant using standard testing with vancomycin broth microdilution (BMD) or Vitek 2. To determine the role of these mutations in the evolution of glycopeptide heteroresistance, extended glycopeptide testing by vancomycin gradient assay (VGA), vancomycin and teicoplanin METs and a vancomycin population analysis profile to area under the curve ratio (PAP:AUC) was performed for each of the WT and rpoB662 mutant pairs. Experiments for the BPH0676-WT and BPH0676-rpoB662 pair are shown in Fig. 4 . Compared to its parental strain, the BPH0676-rpoB662 mutant had a statistically significant increase in mean ratio to BPH0662 for VGA (P = 0.0039) and PAP:AUC (P = 0.0023). Furthermore, the gains observed in both vancomycin and teicoplanin MET MICs for the BPH0676-rpoB662 mutant achieved the criteria for vancomycin heteroresistance. Statistically significant increases in glycopeptide resistance were also observed for the other rpoB662 mutants Articles NATURE MIcROBIOlOgy compared with their respective parental strains ( Supplementary  Fig. 5 ). Having independently validated each mutant compared to their parental strain, the pairs were then analysed collectively. For each phenotypic testing method, a statistically significant increase in mean glycopeptide resistance was observed for the rpoB662 mutant group compared to their paired parental strains (Fig. 5) . These experiments show that D471E and I527M RpoB substitutions cause the vancomycin-heteroresistant phenotype.
Mutants containing dual D471E and I527M RpoB substitutions outcompete WT S. epidermidis in the presence of vancomycin.
To assess the advantage conferred by the dual D471E/I527M RpoB substitutions in the presence of vancomycin, 1:1 competition assays for BPH0736-WT and its rpoB662 mutant were conducted. In the absence of vancomycin, the D471E/I527M RpoB allele posed a substantial fitness cost, with a significant shift to the WT population at 48 h (Fig. 6 ). However, with the introduction of vancomycin the population dynamics reversed and at 48 h with 4 μ g ml −1 vancomycin, the population was 100% rpoB662 mutant (Fig. 6) . Individual growth curves for each of the WT and rpoB662 mutant pairs were not significantly different in the absence of antibiotics ( Supplementary  Fig. 6 ). These experiments confirm that the D471E and I527M RpoB substitutions in S. epidermidis were capable of generating both highlevel rifampicin resistance as well as vancomycin heteroresistance in S. epidermidis strains from divergent backgrounds.
Discussion
We have uncovered here the emergence of three genetically distinct MDRSE lineages, with common dual D471E and I527M RpoB substitutions, that have evolved within the hospital environment to exhibit near pan-drug resistance. The presence of the same mutations in multiple phylogenetically distant lineages is consistent with independent emergence of these mutations with subsequent fixation, presumably due to their favourable antibiotic-resistant phenotype. The international prevalence of these dual mutations, as determined in this study, suggests that a high proportion of rifampicin-resistant clinical S. epidermidis isolates possess mutations that also confer glycopeptide heteroresistance, not detectable by standard diagnostic methods. Although dominance may vary by region, the same three lineages, with low intra-group genomic diversity, were demonstrated to be endemic and co-circulate within multiple institutions worldwide, suggesting their unrecognized presence in other establishments. The diminishing pool of antibiotics available for the treatment of infections due to such isolates, and the increasing catalogue of complex genetic interactions that contribute to antimicrobial resistance between unrelated drug classes, reinforces the need for the judicious utilization of remaining therapeutic options.
In particular, this research has implications for how rifampicin is utilized in clinical practice. Device impregnation with rifampicin is of particular concern, as low-level rifampicin monotherapy released in this situation could predispose colonizing 
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S. epidermidis to develop rifampicin resistance and concomitant vancomycin heteroresistance. To avoid generating resistance with monotherapy, combination therapy is recommended when using rifampicin for the treatment of staphylococci 31, 32 . Historical studies describing dual therapy with vancomycin and rifampicin for S. epidermidis prosthetic valve endocarditis 33 have informed current staphylococcal clinical guidelines 31 . However, the emergence of rifampicin resistance when using this treatment combination for serious infections has been reported for both S. epidermidis 34 and S. aureus [35] [36] [37] . Our results suggest that co-prescription of vancomycin and rifampicin will promote the generation of resistance to both agents, although additional experiments are required to test this hypothesis. Widespread loss of vancomycin as a first-line treatment option against S. epidermidis would have significant clinical impact, especially in view of the limited available substitutes. While alternative agents such as daptomycin, ceftaroline, lipoglycopeptides and linezolid exist, staphylococcal resistance to all has been described 36 . Considered in this context, our confirmation of a causal association between rifampicin resistance mutations and vancomycin heteroresistance in S. epidermidis, together with clinical reports demonstrating lack of cross-protection, suggest that current clinical recommendations warrant review. Alarmingly, our study has identified that near untreatable isolates already exist, with two German vancomycin heteroresistant isolates, one ST2-mixed (GER16) the other an ST23 clone (GER15), also testing as resistant to both daptomycin and linezolid, with tetracycline the only antibiotic option remaining ( Supplementary Fig. 1 ).
Surveillance is not routinely performed for S. epidermidis, and consequently there are no robust data on the prevalence of rifampicin resistance in this species. Reference laboratories may be sent MDRSE isolates of clinical concern, but no denominator data exist to determine the background number of susceptible isolates. The data from individual centres contributing to this study suggested local variation in the annual prevalence of S. epidermidis rifampicin resistance at each institution between 2012 and 2017: 10% increasing to 20% for Erasme Hospital, Belgium; 10% for Monash Health, Australia; 6% for Hvidovre Hospital, Denmark; and 3% for Mayo Clinic, Rochester, MN, USA. These rates included all S. epidermidis isolated from clinical samples for each institution, and almost certainly underestimated the prevalence in clinically significant isolates. This was highlighted by our Australian data, which demonstrated that despite only 10.8% of all S. epidermidis isolated from blood cultures in the state of Victoria over the month of March 2017 testing rifampicin-resistant, 30.0% of the clinically significant isolates were rifampicin-resistant (all of which were vancomycin-heteroresistant). In view of the ubiquitous nature of S. epidermidis and difficulties distinguishing colonizing from clinically significant isolates, determining the true prevalence of these MDRSE lineages is likely to remain a challenge. Therefore, rifampicin resistance is a potentially useful marker for identifying these clinical S. epidermidis clones.
The retrospective nature of the isolate collection we used, which was biased towards the acquisition of multidrug-resistant S. epidermidis, is a limitation of this study, and sampling may have missed some less prevalent genotypes. Furthermore, we did not have access to data regarding the treatment received or clinical outcomes of the patients from whom isolates were obtained. Notwithstanding these limitations, we obtained a good representation of the international diversity of rifampicin resistance in clinical S. epidermidis, which was the main focus of this study. Having identified the existence of three MDRSE S. epidermidis lineages with international presence, future research could include more geographically diverse, prospective sampling of isolates with associated clinical data to include treatment and outcomes, which could better delineate the global extent of these clones and offer insight into the clinical impact of these lineages. Our findings indicate that similar glycopeptide resistant isolates are likely to be present within other institutions but unrecognized by standard phenotypic testing methods, highlighting a need for clinical vigilance. These data challenge current assumptions that cross-protection is afforded by the co-prescription of rifampicin and vancomycin for the treatment of staphylococci, indicating that a review of clinical guidelines is warranted to avoid the further selection of near untreatable clones.
Methods
Media and reagents. S. epidermidis and S. aureus were routinely cultured at 37 °C in BBL brain heart infusion (BHI) broth (Becton Dickson). For electroporation, S. epidermidis was cultured in B medium (1% peptone, 0.5% yeast extract, 0.5% NaCl, 0.1% K 2 HPO 4 , 0.1% glucose). Escherichia coli was routinely cultured in L broth (1% tryptone, 0.5% yeast extract, 0.5% NaCl). BMD minimum inhibitory concentrations (MICs) were performed in cation-adjusted Mueller Hinton (MH) broth (Difco). For growth on agar, BHI or L broth were solidified with 1.5% agar, to yield BHIA and LBA, respectively. The following antibiotics were purchased from Sigma Aldrich and used at the specified concentrations: chloramphenicol (Cm) 10 μ g ml −1 for S. epidermidis, 15 μ g ml −1 for E. coli; ampicillin (Amp) 100 μ g ml −1 for E. coli; kanamycin (Kan) 50 μ g ml −1 for E. coli. The following antibiotics were used at variable concentrations for susceptibility testing: rifampicin (Sigma Aldrich) and vancomycin (Hospira).
Oligonucleotides were purchased from Integrated DNA Technologies and are listed in Supplementary Table 3 . Genomic DNA was isolated with DNeasy Blood and Tissue Kit (Qiagen). To weaken the cell wall of S. epidermidis before DNA extraction, harvested cells were washed with PBS. Lysostaphin (Ambi) was added to the Gram-positive lysis buffer (final concentration 100 μ g ml , with the percentage of rifampicin resistant (RIF R ) to rifampicin susceptible (RIF S ) isolates determined by plate count. All data points for biological triplicate experiments are displayed. Horizontal lines depict mean and error bars show standard deviation. Null hypothesis (no difference between means) was rejected for P < 0.05. Differences assessed using two-way analysis of variance (ANOVA) with Tukey's test for multiple comparisons. ***P < 0.001, ****P < 0.0001.
Antibiotic susceptibility testing. The background antibiogram of S. epidermidis for Austin Health from 2007 to 2013 was determined by collating all routine isolates that had susceptibility testing performed (interpreted according to Clinical and Laboratory Standards Institute (CLSI) criteria), excluding duplicate strains obtained from the same patient. Comparator isolates underwent susceptibility testing with a Vitek 2 Gram Positive ID card (AST-P612; bioMérieux) on a Vitek 2 (bioMérieux) according to the manufacturer's instructions. BMD MICs for vancomycin and rifampicin were performed as recommended by CLSI 39 . Rifampicin Etests (bioMérieux) were performed according to the manufacturer's instructions. Extended glycopeptide susceptibilities were determined by MET with vancomycin and teicoplanin Etest strips (bioMerieux) using a 2.0 McFarland inoculum and prolonged incubation time of 48 h. S. aureus criteria for vancomycin heteroresistance were used (vancomycin and teicoplanin MET of > 8; teicoplanin MET alone of > 12), as no criteria have been defined for S. epidermidis. Vancomycin PAPs were performed as previously described 40 , but overnight S. epidermidis cultures were adjusted to an optical density at 600 nm (OD 600 ) of 0.4. For VGAs, 50 ml of BHIA supplemented with vancomycin 4 μ g ml
was set in a 10 cm square Petri dish with one side elevated at a 5° angle (to form a two-dimensional gradient); the Petri dish was then placed level and a second 50 ml BHIA layer was set over the vancomycin layer. Plates were used within 48 h. Overnight cultures of tested strains were standardized to an OD 600 of 0.08 in BHI and a 10 μ l loop was used to streak the strain across the plate from vancomycin 0 to 4 μ g ml −1
. Distance of growth was measured in mm after 48 h incubation at 37 °C, and expressed as a ratio to growth of control strain, BPH0662. With the exception of Vitek 2 and Etests, all antibiotic susceptibility testing of strains was performed in biological triplicate. Interpretation of all phenotypic testing was blinded, with the exception of VGAs due to the pairing of mutant and parental isolates on the same gradient plate to ensure consistent experimental conditions. Genome sequencing. Draft genomes of the 222 clinical comparator strains, the isolates of RP62a and ATCC 12228 used to create mutant strains, four rpoB mutant Genome analysis. Illumina paired-end reads were trimmed using Trimmomatic v0.36 41 , and overlapping pairs merged with PEAR v0.9.10 42 . Draft genomes were de novo assembled with SPAdes v3.7.1 43 using the unassembled R1 and R2, and merged read pairs as input. Genome annotation was performed with Prokka v1.12 44 . An alignment of core genome SNPs across the S. epidermidis isolates was determined using Snippy v3.2 45 using the closed BPH0662 genome as a reference. iqtree v1.5.3 46 using model finder 47 and ultrafast bootstrap 48 was then used to produce a maximum-likelihood phylogenetic tree. Pairwise SNP analysis was performed using pairwise_snp_differences 49 . For pan-genome analysis, protein orthologue clustering was performed using Proteinortho v5.11 50 , alignment of the resultant CDS orthologues to BPH0662 and visualization of the pan-genome were performed using FriPan 51 . De novo assemblies were genotyped using in silico MLST 52 , and the resistome and virulome were characterized with abricate 53 screened against the NCBI Bacterial Antimicrobial Resistance Reference Gene Database (NCBI BARRGD, PRJNA313047) and Virulence Factors of Pathogenic Bacteria Database (VFDB) 54 , respectively. The tree was clustered using a hierarchical Bayesian Analysis of Population Structure (hierBAPS) model 55 .
To infer the evolutionary phylogeny of ST2 S. epidermidis, regions of phage insertion and recombination were masked to ensure modelling was only informed by spontaneous SNPs within the core genome. Five (BPH0704, BPH0697, BPH0677, BPH0737 and SEI) of the 227 isolates were omitted from final analyses based on their extreme divergence, which suggested either excessive natural selection, thereby violating the assumption of evolutionary neutrality used in the model, or separation of these lineages so remotely in the past as to be beyond the abilities of this method to analyse correctly. Two historical, non-MDRSE Australian clinical isolates (BPH0823 isolated in 1989 and BPH0825 isolated 1990) were included to improve temporal sampling depth. Snippy v3.2 45 was used to generate an alignment of the 224 relevant isolates to the full BPH0662 chromosome. Phage elements in the BPH0662 reference were identified using PHASTER 56 and masked from the alignment with BEDtools 57 . Gubbins v2.2.0 58 was used to filter recombination and identify core-SNPs from filtered alignment, with RAxML v8.2.10 59 for tree building. A final maximum-likelihood tree was produced with iqtree v1.5.3 using model finder and ultrafast bootstrap. BEAST v2.4.3 60 was used to generate a timed phylogeny (chronogram) assuming a relaxed clock and using coalescent tree prior. The assumption of a molecular clock was tested using root-to-tip distance in R v3. 4 61 using the Analysis of Phylogenetics and Evolution (APE) package v4.1 62 . All publicly available S. epidermidis genome raw reads in NCBI SRA were downloaded (4 November 2016) and assembled as described above. Exclusion criteria were as follows: sequencing performed on a Roche 454 or Ion Torrent platform (per Genbank metadata); single end reads; sequencing depth of < 30× ; isolates sequenced as part of this study; mutagenesis isolate pairs; organism not S. epidermidis or sequencing of mixed bacterial species as determined by Kraken v0.10.15beta 63 ; > 300 assembled contigs; raw reads not associated with publications and lacking metadata. When isolates were identified as exact genetic replicates, a single representative was used in analysis. To determine the diversity of mutations in RpoB, the RpoB translation for ATCC 12228 (accession no. NP_763861) was used as reference for a tblastn query on the combined NCBI SRA and study isolate assemblies using BLAST+ v2.6.0 64 , the output of which was aligned with MUSCLE v3. 8.1551 ; this was then manually collated with the RpoB mutations reported in ref. 30 . To determine the RRDR of RpoB for S. epidermidis the RpoB translations for ATCC 12228 and BPH0662 were aligned with the published 27-amino-acid RRDR defined for E. coli and M. tuberculosis 28, 29 and S. aureus 29 . Using the above method, the following reference nucleic acid/gene translations from ATCC 12228 were used to screen for the presence of mutations conferring linezolid resistance: 23S rRNA (GeneID 3190203), L3 (NP_765379), L4 (NP_765378) and L22 (NP_765374). For Mprf, the gene translation from RP62a was used as the reference (WP_002456532).
Bacterial transformation. Overnight cultures of S. epidermidis grown in 10 ml of B medium were diluted to an OD 600 of 0.5 in 100 ml of fresh, prewarmed B medium. Cultures were then reincubated for 40 min and chilled in an ice slurry for 10 min. All subsequent steps were performed as previously described 38 , with the exception of post-electroporation recovery in which cells were incubated in 1 ml of BHI supplemented with 500 mM sucrose (filter sterilized) at 28 °C for 1 h before plating on BHIA Cm10.
Construction of E. coli Ec_Se662I-II for transformation of ST2 S. epidermidis. The E. coli Ec_Se662I-II mutant expressing both BPH0662 type I RM systems in a DC10B background was constructed using a previously described protocol and primers 12 . The DC10B-MS1 mutant with hsdMS1 integrated between essQ and cspB was subjected to a second recombination event to integrate hsdMS2 between ybbD and ylbG.
Allelic exchange of rpoB using pIMAY. To construct pIMAY(rpoB662), pIMAY 38 was linearized with KpnI and gel extracted; the vector backbone was then amplified from within the multiple cloning site (MCS) with primers IM1/IM2. The entire Articles NATURE MIcROBIOlOgy rpoB gene of rifampicin-resistant, reference strain BPH0662 was amplified using primers rpoB3/rpoB4 (incorporating flanking KpnI sites), and the product gel extracted. Seamless ligation cloning extract (SLiCE) was used to insert the rpoB construct into the pIMAY vector backbone, as previously described 66, 67 . After transformation into E. coli Ec_Se662I-II, the rpoB insert was verified by Sanger sequencing and the vector pIMAY(rpoB662) subsequently electroporated into four rifampicin-susceptible S. epidermidis strains: BPH0676, BPH0736, RP62a and ATCC 12228. Transformants were selected for on BHIA plus Cm after 2 days at 28 °C. Integration and excision of pIMAY(rpoB662) was performed as previously described 38 , with the exception of concurrent (rather than sequential) colony PCRs, for loss of replicating plasmid (with MCS primers IM3/IM4), and chromosomal integration of the plasmid upstream (rpoB out forward/IM3) and downstream (IM4/rpoB out reverse). Plasmid excision in favour of mutant creation was selected for on BHIA plus ATc1 (Sigma) with rifampicin at 4, 8, 16 or 32 μ g ml −1 , large colonies were patch-plated on BHIA plus Cm10 and BHIA plus rifampicin at 4, 8, 16 or 32 μ g ml −1 and grown at 37 °C overnight, with successful mutants bearing a Cm S , Rif R phenotype. Potential mutants were selected from the plate containing the lowest rifampicin concentration. Stability of Rif R mutants was confirmed by overnight growth on BHIA without antibiotics, with subsequent restreaking on BHIA plus rifampicin 32. Draft genomes of successfully created mutant strains (BPH676-rpoB662, BPH0736-rpoB662, RP62a-rpoB662 and 12228-rpoB662,) and the parental strains from which they were derived (BPH0676, BPH0736, RP62a and ATCC 12228, respectively) were sequenced to determine if any unintended mutations were present. Variant calling between the rpoB662 mutants to their respective WT parental strains was cross-checked by two methods, using Snippy 45 and Nesoni 68 . Mutants and their corresponding parental strains were subjected to phenotypic testing to determine the role of rifampicin resistance mutations (D471E and I527M) in RpoB on the evolution of glycopeptide heteroresistance in S. epidermidis.
Growth curves and vancomycin competition assay. For growth curves, overnight cultures were diluted to an OD 600 of 0.05 in 50 ml of prewarmed BHI and grown at 37 °C with aeration at 200 r.p.m. The OD 600 values were measured hourly for 12 h. Growth curves were performed in biological triplicate. The doubling time for each strain was calculated as previously described 69 , using the 2 and 5 h exponential phase time points. For vancomycin co-culture assays, overnight cultures of WT and the corresponding rpoB662 mutant strain were diluted to an OD 600 of 0.5 in BHI, 0.5 ml of each culture was added to 49 ml of BHI containing vancomycin at 0, 2 or 4 μ g ml −1 (starting OD 600 of co-cultures = 0.01). Cultures were incubated at 37 °C with aeration at 200 r.p.m. For vancomycin 0 and 2 μ g ml
, co-cultures reached saturation by 24 h and the medium was refreshed with a 1/1,000 dilution of the 24 h co-culture in 50 ml of BHI containing vancomycin at 0 and 2 μ g ml
, respectively. Cultures were incubated at 37 °C with aeration at 200 r.p.m, for a further 24 h (48 h total). The vancomycin 4 μ g ml −1 co-culture did not reach saturation until 48 h, so the medium was not refreshed at 24 h. Serial dilutions of each co-culture were performed at times 0, 24 and 48 h, plated on BHIA and incubated at 37 °C overnight; colonies were then patched onto BHIA plus rifampicin 32 μ g ml −1 to determine the proportion of WT to rpoB662 mutant. Statistical analysis. Etest MICs were log 2 -transformed to normalize the distribution before statistical analysis. All statistical analyses (Mann-Whitney U test, unpaired or paired Student's t-test, two-way ANOVA with Tukey's test) were performed with GraphPad Prism 7 for Mac OS X (GraphPad Software), with the exception of the pairwise SNP analysis which was performed using pairwise_snp_ differences 49 All studies must disclose on these points even when the disclosure is negative.
Sample size
No sample size calculation was performed. This research was based on genomic interpretation of a retrospective survey of a global collection of bacteria that were samples of convenience. We did not establish this study to test the effect of an experimental intervention or specific hypothesis. Thus, there is no null hypothesis to reject and no sample size calculation was performed. To present an accurate global description of the isolates responsible for clinical S. epidermidis infection, broad sampling was performed to maximise both temporal and geographical representation. The 419 isolates analysed were sampled from 96 institutions in 24 countries, isolated over a 62-year period spanning 1955 to 2017. Furthermore, all but two of the reference isolates were of clinical origin to ensure the relevance of results to clinical practice.
Data exclusions S. epidermidis RpoB mutation frequency analysis: 324 of 484 S. epidermidis raw reads available on NCBI were excluded as per the criteria listed in the methods section of the manuscript. These isolates were sequenced as part of microbiome projects, with resultant poor sequencing coverage and/or contaminated reads mixed with other species; or sequenced using older chemistry known to be error prone. The low quality assemblies produced from these raw reads would have confounded analyses with artificial mutations, therefore these data were not included.
Replication
To demonstrate a causal relationship between the dual D471E and I527M RpoB substitutions and a vancomycin heteroresistant phenotype in S. epidermidis, mutants possessing these substitutions were made in four different backgrounds, from 3 different lineages (ST2, ST8 and ST10). Extended glycopeptide susceptibility testing for the four mutant and wild-type pairs was performed using three different methods (vancomycin population analysis profile, vancomycin plus teicoplanin macromethod Etests and vancomycin gradient assay); testing was performed in biological triplicate. A statistically significant increase in glycopeptide tolerance was demonstrated for each mutant compared to its respective parental isolate by each of the three phenotypic methods, thereby proving the hypothesis that the dual D471E and I527M substitution in RpoB confers both rifampicin resistance and glycopeptide heteroresistance in S. epidermidis.
Randomization Randomisation was not relevant to this study as all isolates were subjected to the same phenotypic and genomic analyses in order to fully characterise the dataset.
Blinding
Interpretation of all phenotypic testing was blinded with the exception of vancomycin gradient assays due to the pairing of mutant and parental isolates on the same plate (as shown in Figure 4 and Supplementary Figure 5 ) to ensure consistent experimental conditions. All four mutant and wild-type pairs were subject to a two additional phenotypic methods to characterise glycopeptide heteroresistance (vancomycin population analysis profile and vancomycin plus teicoplanin macromethod Etests) the interpretation of which were blinded to ensure no bias.
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